Skip navigation
>»
RSS feed for this page
Know something we don't? Submit a conference announcement
Choose Category:

Pharmacoeconomics meetings & conferences

5 meetings & conferences listed in Pharmacoeconomics 

World Congress Leadership Summit on Optimizing Oncology Management
United States
Massachusetts
08/02/2012

World Congress Leadership Summit on Optimizing Oncology Management

August 2-3, 2012 Boston Massachusetts

The Annual World Congress Leadership Summit on Optimizing Oncology Management provides best practices and updates to the entire oncology industry, specially focusing on the payer and how they are to handle policy and program formation.

With the influx of oncology products in manufacturer pipelines and the rising cost of treatment, it is now more imperative than ever for plans to properly contain spending while providing the best possible quality of care. As more drugs and therapies start target similar molecular pathways, competition is bound to increase. This conference will help plans evaluate the jungle of treatments out there to pin point the best coverage for their members.

New for 2012:

What new developments are in the manufacturer pipelines and how to properly prepare for them
Case Studies of oncology benefit programs that enhance member experience and quality of life
Realize cost savings by comparing and analyzing current treatments to determine efficiency
Discuss how different future models of health care delivery will affect oncology treatment access
Learn what employers are concerned about in regards to oncology benefits for their employees

Health Economist, Health Services Researcher, Healthcare Administrator, Oncologist, Pharmacist, Policy Analyst
4th Annual Personalized Medicine Conference
United States
Massachusetts
09/12/2012

4th Annual Personalized Medicine Conference

September 12-13, 2012 Boston, Massachusetts

Personalized medicine has the potential to revolutionize medical care by utilizing an improved understanding of genetics and molecular biology to allow for better diagnostic tests, more precise diagnoses, greater predictability of disease course, and improved patient safety by selecting not only the right drug for a patient but also the proper dosage to reduce adverse effects. Speakers and panelists will answer the following key questions:

What types of challenges need to be met in order to realize the true commercial potential of personalized medicine?
Will insurers fund the genomic revolution?
What types of validation requirements are they looking for?
What will be their criteria for reimbursement?
What are the real-world challenges to successful adoption of molecular/companion diagnostics?
Who needs to partner in order to advance the field of personalized medicine?
What are the goals, utility and challenges associated with Rx-Dx partnerships?
How and when are relationships being initiated today?
How are companies navigating their way through the world's regulatory bodies?
What kind of impact are Pharmacy Benefit Managers (PBMs) and for that matter new genetic testing benefit managers going to have on the future of personalized medicine?
What types of efforts are being made to influence adoption via physician education?

Arrowhead Publishers and Conferences
5412 Irving Avenue South
Minneapolis
MN
55419
USA

E-mail: enquiries@personalizedmedicinepartnerships.com
Telephone: 312-244-3703
Fax: 312-244-3703
http://www.arrowheadpublishers.com

African American, Clinical Pharmacist, Health Economist, Health Services Researcher, Healthcare Administrator, Molecular Biologist, Pharmacist, Policy Analyst
International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting
United States
Washington, DC
06/02/2012

International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting

June 2-6, 2012 Washington, DC

Health Economist, Pharmacist
Drug Information Association 2012 Annual Meeting
United States
Pennsylvania
06/24/2012

Drug Information Association 2012 Annual Meeting

Collaborate to Innovate

June 24-28, 2012 Philadelphia, PA

DIA 2012: Collaborate to Innovate is the largest multidisciplinary event that brings together a global network of professionals to foster innovation that will lead to the development of safe and effective health care products.

Through increased access to training and expanded professional networking opportunities, DIA 2012 will:

• Provide a global unbiased platform to raise the level of discussion to facilitate innovation that will change the future of health care
• Provide comprehensive coverage of the full development and life cycle management process for all health care products
• Offer a holistic and integrated approach to the development and life cycle management of regulated health care products

Ultimately, collaboration is about mutual respect, working together, and being open to new ideas and learning from each other. To that end, DIA 2012 provides the best opportunity
to meet with people from around the world, share your views and knowledge, network, and build new relationships.

Questions related to the 2012 Annual Meeting Program? Contact: annualmeetingprogram@diahome.org

Pharmaceutical Scientist, Pharmacologist, Public Health Expert, Public Servant
First Meeting on Patient Reported Outcomes in Mental Health
United States
Washington, DC
09/28/2012

First Meeting on Patient Reported Outcomes in Mental Health

Patient Reported Outcomes and Person Centered Care in Mental Health

Washington D.C., September 28-30, 2012

The Meeting addresses research in PRO assessment and measurement in mental and addictive disorders in the context of person centered and recovery oriented policies. A special track in the meeting will consider severe mental disorders and schizophrenia. The research domains include:

(i) New theoretical, methodological and empirical research on disorder-specific and general PRO instruments and measures regarding items content and psychometrics

(ii) PRO assessment in clinical and general populations. Collection, storage and retrieval of PRO assessment data information over time and the role of IT technology

(iii) Individual vs society perspectives and preferences about health status and interventions, and the role of PRO information in efficacy, effectiveness, comparative effectiveness and cost-effectiveness research

(iv) Co-shared PRO information for co-shared decision making regarding interventions for prevention, treatment, rehabilitation, and person centered care.

(v) Patient’s right of appropriate information and assessment about his/her own PRO and their inclusion in decision making regarding treatment

(vi) Financing of PRO assessment services and use in research and clinical practice

(vii) Role of PRO information in recovery oriented decision making regarding the organization and financing of services and health technologies for mental and addictive disorders.

PATIENT REPORTED OUTCOMES (PRO) – MEDICAL DISEASES AND CONDITIONS

A PRO instrument can be used in medical diseases and conditions to measure the impact of an intervention on one or more aspects of patients’ health status ranging from the purely symptomatic (response of a disturbing experience like pain), to more complex concepts (e.g. ability to carry out abilities of daily living), to extremely complex concepts such as multidimensional quality of life, including physical, psychological, and social components.

Subject areas (not exhaustive):

PRO Measurement

Disorder and condition specific PRO (i.e., Schizophrenia, Bipolar Disorder, Depression, Anxiety, Alcohol Addiction, Drug Addiction)
Overall and General Health Status PRO measures
Content analysis of PRO measures and items
Psychometric analysis of PRO measures
Passively Received Experiences of the disorder and immediate subjective disturbance
Impact of the disorder on subjectively meaningful own school/work, social and recreational activities and on subjectively meaningful life planning
Treatment side-effects, immediate disturbance, impact on subjectively meaningful own school/work, social and recreational activities, and on subjectively meaningful life planning
Subjectively meaningful “Remission” and “Recovery”
Quality of life
Co-morbidities
Psychological impact of psychiatric and medical disorders
Intermediate PRO
Satisfaction with treatment and interventions
Individual and social preferences about condition specific states, general health states, and interventions side-effects

PRO Co-shared Information

Passively received experiences of the disorder and subjective disturbance
PRO symptoms, symptoms trajectory and complications
General Health PRO
Quality of Life PRO
Subjectively meaningful treatment targets and drug treatment side-effects
PRO Co-shared information as co-shared decision-making aid in choices about clinical treatment initiation, refinement and continuation
PRO Co-shared information as co-shared decision-making aid in social interventions

Use of PRO Co-shared Information in Decision Making about Interventions

Clinical and Support Interventions

Preventive services
Outpatient services
Inpatient services
Psychotropic medications
Psychotherapy and Psychological Treatments
Psychosocial treatments
Peer Support
Self-help
Individual, group and social preferences

Social Interventions

Housing
Work
Social Inclusion
Social Security Income and Disability Pensions
Individual, group and social preferences

Right of Access to Information and PRO

Patient’s access to information
Information about disorder-specific and general PROs
Information about efficacy, effectiveness and comparative effectiveness of treatments and interventions on PROs
Patient’s PRO information use in co-shared decision-making
PRO assessment, information, use, storage and retrieval in decision-making and co-shared decision-making about treatment initiation, refinement and continuation.
Right of access to information about PROs and civil rights
Simple and complex levels of own PROs determination and report.
Duties and obligations in person centered PRO information in research and practice
Omission of information about PROs and Negligence
Involuntary treatment commitment policies and practices
Subjective stigma related to disorder, treatment and treatment side-effects
Intentional denial and malingering about PROs
Individual vs society perspectives

Health Economics

Burden of illness
PRO in comparative effectiveness research
PRO in cost-effectiveness and cost-utility research
PRO information, subjective usefulness of interventions and economic behavior
PRO, pricing for pharmaceuticals and value to patients
Financing the right of access to knowledge about PRO information and its use in decision-making
Agency and financing
Self-directed financing of services

Health Policy

Patient’s perspective in mental health policy formulation
Patient’s perspective in the financing and access of interventions for mental and addictive disorders
Person centered and recovery oriented models

INFORMATION

Massimo Moscarelli, MD
International Center of Mental Health Policy and Economics (ICMPE)
Via Daniele Crespi 7
20123 Milano, Italy
E-mail: moscarelli@icmpe.org

FAX +39-02-5810 6901
Website: www.icmpe.org

Behavioral Scientist, Clinical Psychologist, Community Activist, Health Economist, Health Services Researcher, Physician Researcher, Policy Analyst, Psychiatrist, Psychologist, Psychotherapist, Public Health Expert, Public Health Worker, Public Servant, Social Worker